Skip to content
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
IFPMA
  • Who We Are
    • IFPMA in Brief
    • Our Governance and Leadership
    • Our Membership
      • Full Members
        • Associations
        • Companies
      • Affiliate Members
    • Our Experts
    • Join Us
  • Topics
  • News Center
    • News Releases
    • Blog
      • Global Health Matters
      • Science Matters
      • DG’s Column
    • Statements
  • Resources
    • Publications
      • News Releases
      • Statements
      • Position Papers
      • Publications
      • External Studies
      • Infographics
      • Event Highlights
    • Multimedia
      • Interviews
      • Videos
      • Slides
    • IFPMA Interactive Platforms
      • IFPMA COVID-19 Hub
      • Global Health Progress
      • 50 Years of Global Health Progress
  • Events
    • Upcoming IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
      • IFPMA Press Briefings
    • Past IFPMA Events
      • Geneva Pharma Forums
      • Assemblies
      • Other IFPMA Events
      • IFPMA in External Events
      • IFPMA Press Briefings
  • Partners
  • BCR
  • Inventing Medicines and Vaccines
  • Strengthening Regulatory Systems
  • Ethics and Business Integrity
  • Boosting Innovation and Access
  • Tackling Global health challenges
Climate change Economic footprint IP Sustainable innovation Value of innovation

spotlight

Value of innovation

Inventing Medicines and Vaccines
African Medicines Agency Biosimilars Biotherapeutic medicines Falsified medicines Import testing Pharmacovigilance Quality, safety, and efficacy Regulatory conferences Regulatory system strengthening / Harmonization Supply chain The Africa Regulatory Network (ARN) The ARN: Le réseau africain de réglementation pharmaceutique

spotlight

Pharmacovigilance

Strengthening Regulatory Systems
IFPMA Code of Practice (2019) Our Ethos in Action Our Ethos Code eLearning Tool IFPMA Notes for Guidance IFPMA Complaint Operating Procedure How to File a Code Complaint Complaint Submission Form Cases Business Ethics for APEC SMEs Initiative Consensus Framework for Ethical Collaboration

spotlight

IFPMA Code of Practice (2019)

Ethics and Business Integrity
Access to medicines Global Policy Principles on Digital Health Health technology assessment IP Technology Transfer Trade

spotlight

Access to medicines

Boosting Innovation and Access
Ageing Antimicrobial resistance Cancer Child and maternal health COVID-19 Diabetes Ebola Falsified medicines HIV/AIDS Influenza Malaria Mental and neurological disorders Neglected tropical diseases Non-communicable diseases Pandemic Preparedness Public health implications of the implementation of the Nagoya Protocol Rare diseases Supply chain Sustainable development goals Tuberculosis Universal Health Coverage Vaccination confidence Vaccines innovation Vaccines protect communities Vaccines sustainability Value of immunization Viral hepatitis

spotlight

Universal Health Coverage

Tackling Global health challenges
  • Home
  • >
  • Resources
  • >
  • Infographics
  • >
  • Doing our part: landmark medicine donations

Doing our part: landmark medicine donations

Published on: 17 February 2015

IFPMA_Small_Infographic_NTDs_Donations_Feb_2015_FINAL

Downloads

» Infographic

Resources

Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions
Publications

Publications

Pharmaceutical R&D Projects to Prevent and Control Neglected Conditions

Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations
Publications

Publications

Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations

New report shows major increase in pharmaceutical research and development (R&D) for neglected diseases
News Releases

News Releases

New report shows major increase in pharmaceutical research and development (R&D) for neglected diseases

Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations
Publications

Publications

Ending neglected tropical diseases 2012 IFPMA member companies support eliminating and controlling neglected tropical diseases over the next decade through landmark donations

WHA 66, Item 16.2, Neglected tropical diseases
Statements

Statements

WHA 66, Item 16.2, Neglected tropical diseases

Open letter to G7 Heads of State on neglected tropical diseases
News Releases

News Releases

Open letter to G7 Heads of State on neglected tropical diseases

Related Topics

Neglected tropical diseases

Tags

  • Capacity
  • Donations
  • IFPMA
  • Infographics
  • Medicines
  • Neglected Tropical Diseases
  • NTDs
  • Partnerships
  • PDPs
  • Pharma
  • Pharmaceuticals
  • R&D
  • Research
  • Vaccines
IFPMA

Chemin des Mines 9
1202 Geneva
Switzerland

+41 22 338 32 00
info@ifpma.org

  • File a Code Complaint
  • Privacy Policy
  • Terms of Use
  • Access to Our Extranet
  • Careers
  • Contact Us
  • IFPMA Twitter
  • IFPMA LinkedIn
  • IFPMA Youtube
  • IFPMA Slideshare
  • IFPMA Flickr
  • IFPMA RSS
Designed and Produced by ACW
^ Back to Top